Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy

Head and Neck

Volumn 31, Issue 4, 2009, Pages 442-451

  Wang, Yi Fen ^a   Liu, Ren Shyan ^a   Chu, Pen Yuan ^a   Chang, Feng Chi ^a   Tai, Shyh Kuan ^a   Tsai, Tung Lung ^a   Huang, Jui Lin ^a   Chang, Shyue Yih ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Chemoradiotherapy; Computed tomography; Head and neck squamous cell carcinoma; Metastasis; Positron emission tomography

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; HYPOPHARYNX CARCINOMA; INTERMETHOD COMPARISON; LARYNX CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM METASTASIS; MOUTH CARCINOMA; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; OROPHARYNX CARCINOMA; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RIB; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 65649093384     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20978     Document Type: Article

References (37)

1. Chen GS, Chen CH. A statistical analysis of oral squamous cell carcinoma. Kaohsiung J Med Sci 1995;11:582-588.
2. Hsieh LL, Wang PF, Chen IH, et al. Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quit chewing and cigarette smoking in Taiwanese. Carcinogenesis 2001;22:1497-1503.
3. Vokes EE, Haraf DJ, Kies MS. The use if concurrent chemotherapy and radiotherapy for locoregionally advanced head and neck cancer. Semin Oncol 2000;27:34-38. (Pubitemid 30643363)
4. McHam SA, Adelstein DJ, Rybicki LA, et al. Who merits a neck dissection after definitive chemoradiation for N2- N3 squamous cell head and neck cancer? Head Neck 2003;25:791-798.
5. Kapoor V, Fukui MB, McCook BM. Role of 18FFDG PET/CT in the treatment of head and neck cancers: posttherapy evaluation and pitfalls. Am J Radiol 2005;184:589-597. (Pubitemid 46657272)
6. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro- D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135-141.
7. Fischbein NJ, AAssar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/ recurrent squamous cell carcinoma of the head and neck. Am J Neuroradiol 1998;19:1189-1196.
8. 18Ffluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999;109:970-975.
9. Yao M, Lu H, Graham MM, et al. FDG PET accuracy in assessment of treatment response in head and neck cancer after intensity modulated radiotherapy - long-term outcome report. Int J Radiat Oncol Biol Phys 2007;69:S14.
10. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2007;133:435-440.
11. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
12. Keyes JW Jr, Watson NE Jr, Williams DW III, et al. FDG PET in head and neck cancer. Am J Radiol 1997;169:1663-1669.
13. Greven KM, Williams DW III, McGuirt WF Sr, et al. Serial positron emission tomography following radiation therapy of patients with head and neck cancer. Head Neck 2001;23:942-946.
14. Terhaard CH, Bongers V, van Rijk PP, et al. F-18-fluorodeoxy- glucose positron-emission-tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001;23:933-941.
15. 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 2005;115:2029-2034.
16. Yao M, Graham MM, Hoffman HT, et al. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2004;59:1001-1010.
17. Ware RE, Matthews JP, Hicks RJ, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck 2004;26:1008-1017.
18. Yao M, Graham MM, Smith RB, et al. Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report. Int J Radiat Oncol Biol Phys 2004;60:1410-1418. (Pubitemid 39610495)
19. Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005;115:645-650. (Pubitemid 40530014)
20. McCollum AD, Burrell SC, Haddad RI, et al. Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 2004;26:890-896.
21. Rogers JW, Greven KM, McGuirt WF, et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys 2004;58:694-697.
22. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005;27:175-181.
23. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005;63:991-999.
24. Wanebo HJ, Chougule P, Akerley WL III, et al. Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg 1997;174:518-522.
25. Merlano M, Vitale V, Rossi R, et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Eng J Med 1992;327:1115-1121.
26. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. EORTC head and neck cooperative group. J Natl Cancer Inst 1996;88:899.
27. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Eng J Med 2003;349:2091-2098.
28. Lefebvre J, Chevalier D, Luboinski B, et al. Long term results of the EORTC 24891 randomized trial on larynx preservation in hypopharyngeal SCC. In: American Head and Neck Society, editors. Final program and abstract book, Sixth International Conference on Head and Neck Cancer, Washington, DC. 2004;s001. p 212.
29. Lapela M, Eigtved A, Jyrkkio S, et al. Experience in qualitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000;36:858-867.
30. Adams S, Baum RP, Stuchensen T, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-1260.
31. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004;130:1361-1367.
32. Quon A, Fischbein NJ, McDougall IR, et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 2007;48(Suppl 1):58S-67S.
33. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in head and neck. Eur J Nucl Med 1999;26:1345-1348.
34. Koike I, Ohmura M, Hata M, et al. FDG-PET scanning after radiation can predict tumor regrowth three months later. Int J Radiat Oncol Biol Phys 2003;57:1231-1238.
35. Kutler DI, Wong RJ, Schoder H, Kraus DH. The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer. Curr Opin Otolaryngol Head Neck Surg 2006;14:73-81.
36. Yao M, Luo P, Hoffman HT, et al. Pathology and FDG PET correction of residual lymph nodes in head and neck cancer after radiation treatment. Am J Clin Oncol 2007;30:264-270.
37. Gordin A, Golz A, Keidar Z, Daitzchman M, Bar-Shalom R, Israel O. The role of FDG-PET/CT imaging in head and neck malignant conditions: impact on diagnostic accuracy and patient care. Otolaryngol Head Neck Surg 2007;137:130-137. (Pubitemid 46962148)